VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

iwMyeloma 2015 | Emerging monoclonal antibodies for the treatment of multiple myeloma

Rafael Fonseca • 11 Apr 2015
iwMyeloma 2015
Multiple Myeloma Antibodies Elotuzumab

At the Myeloma 2015 meeting, Dr Rafael Fonseca (Mayo Clinic, Scottsdale, AZ) discusses novel monoclonal antibodies (mAbs) for the treatment of multiple myeloma. Anti-CD38 mAbs and elotuzumab are showing promising activity in clinical development.

More from Rafael Fonseca

1:26
MRD in multiple myeloma: determining response
Rafael Fonseca • 1 Jun 2018
1:26
CRB-401: is CAR T-cell therapy the future of multiple myeloma treatment?
Rafael Fonseca • 1 Jun 2018
2:40
BCL2 family changes associated with venetoclax resistance in multiple myeloma
Rafael Fonseca • 12 Dec 2021
1:43
Bispecific antibody therapies for myeloma at ASH 2020
Rafael Fonseca • 8 Dec 2020

Related Videos

4:28
A.R.R.O.W. study: carfilzomib dosing in frail MM patients
Maria-Victoria Mateos
1:16
Managing CRS in myeloma
Nina Shah
2:26
Managing transplant patients during the COVID-19 pandemic
Christian Chabannon
3:43
DNA methyltransferase inhibitors: daratumumab enhancement for MM
Priya Choudhry
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals